Literature DB >> 7234772

Medroxyprogesterone therapy for sexual precocity in girls.

P A Lee.   

Abstract

An evaluation of 13 girls who had been treated intramuscularly with medroxyprogesterone acetate for sexual precocity showed that this drug has no effect on growth, skeletal maturation, or adult height. During treatment (mean duration, 3.6 years), menstruation was suppressed and breast size initially regressed, but breast development and public hair development progressed during long-term therapy. The extent of delay in resumption of menses after cessation of therapy was related both to duration of treatment and dosage of the drug.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7234772     DOI： 10.1001/archpedi.1981.02130290041015

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN： 0002-922X


  11 in total

1.  Sexual precocity: clinical profile and laboratory evaluation.

Authors:  K M Kumar; A C Ammini; P S Menon; M L Khurana; M G Karmarkar; M M Ahuja
Journal:  Indian J Pediatr       Date:  1987 Nov-Dec       Impact factor: 1.967

2.  Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist.

Authors:  W Oostdijk; R Hümmelink; R J Odink; C J Partsch; S L Drop; F Lorenzen; W G Sippell; E A van der Velde; H Schultheiss
Journal:  Eur J Pediatr       Date:  1990-02       Impact factor: 3.183

3.  Growth in precocious puberty.

Authors:  Justin J Brown; Garry L Warne
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

Review 4.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

5.  The long-term effect of cyproterone acetate on growth in girls with idiopathic precocious puberty. Androcur Study Group in Japan.

Authors:  K Kato; M Fujimoto; I Hibi; S Suwa; N Shimizu
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

6.  Precocious puberty: auxological criteria discriminating different forms.

Authors:  F Bassi; O Bartolini; A S Neri; R G Gheri; S Bucciantini; D Cheli; V Bruni
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

Review 7.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

8.  Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).

Authors:  J P Bourguignon; G Van Vliet; M Vandeweghe; P Malvaux; M Vanderschueren-Lodeweyckx; M Craen; M V Du Caju; C Ernould
Journal:  Eur J Pediatr       Date:  1987-11       Impact factor: 3.183

9.  Usefulness of early morning urine estrone-3-glucuronide assay in the monitoring ovarian secretory function in precocious puberty.

Authors:  F Bassi; O Bartolini; A S Neri; R G Gheri; A Magini; S Bucciantini; V Bruni
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

Review 10.  A Critical Appraisal of the Effect of Gonadotropin-Releasing Hormon Analog Treatment on Adult Height of Girls with Central Precocious Puberty.

Authors:  Abdullah Bereket
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.